CMA issues charges in second pay-for-delay case

The UK’s competition authority has accused two pharmaceutical companies of entering anticompetitive agreements that boosted prices the country’s National Health Service paid for  anti-inflammatory drug hydrocortisone

Get unlimited access to all Global Competition Review content